What Researchers Did
Researchers treated six patients experiencing long-lasting COVID-19 symptoms with hyperbaric oxygen therapy and assessed their symptoms before, during, and after treatment.
What They Found
All six patients showed improvements in measured symptoms after hyperbaric oxygen therapy. Specifically, five of six patients returned to their pre-infection symptom levels, while the remaining patient experienced significant symptom improvement. These results suggest HBO2 therapy improved symptom scores, reduced symptom duration, and enhanced quality of life.
What This Means for Canadian Patients
While promising, these preliminary findings suggest hyperbaric oxygen therapy might offer a potential treatment avenue for lingering COVID-19 symptoms. However, Canadian patients should await larger, more robust studies before considering this therapy, as its effectiveness and safety are not yet definitively established.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or participants.
Study Limitations
The main limitation of this study is its very small sample size of only six patients, which prevents generalizable conclusions and necessitates larger, randomized controlled trials.